Malgré ses limitations, cette sous-étude de la cohorte ECLIPSE a permis de mettre en évidence l’importance d’une analyse approfondie de la composition corporelle dans l’élaboration du tableau clinique et de la survie des patients atteints d’une MPOC. Elle soulève cependant certaines questions quant à la prise en charge actuelle de la MPOC puisque cette pathologie s’accompagne fréquemment d’anomalies importantes et cliniquement significatives de la composition corporelle et musculaire qui devront être prises en compte dans une prise en charge globale de la maladie.
L’importance de la composition corporelle contribue à consolider la vision d’une prise en charge multi-systémique et multidisciplinaire de la MPOC. La MPOC comporte sont lot de comorbidités et favorise l’apparition d’autres complications de santé comme la MCV et l’obésité. Dans l’objectif d’améliorer la prise en charge du patient dans son intégrité biopsychosociale, il devient plus qu’urgent d’adapter la pratique médicale actuelle. Ces changements devront débuter par une évaluation plus complète des patients et d’y inclure l’analyse de la composition corporelle afin de les considérer dans leur globalité, permettant ainsi de mettre en place une véritable approche multidisciplinaire ayant comme principal objectif le bien-être du patient.
Bibliographie
1. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal.
2004;23(6):932–946.
2. Ehrman JK. ACSM Resource Manual Guidelines for Exercise Test and Prescription. Vol 37. 2010.
3. Snider GL. 1. Changes in COPO Occurrence. Am Rev Respir Dis. 1989;140(3_pt_2):S3–S8.
4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. European Respiratory Journal. 2006;28(3):523–532.
5. Public Health Agency of Canada. Life and Breath: Respiratory Disease In Canada. Public Health Agency of Canada, ed. AIMS Public Health. 2007;2(1):52–43.
6. Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest. 2007;131(1):29–36.
7. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax. 2006;61(12):1043–1047.
8. Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respiratory Medicine.
2008;102(3):413–421.
9. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. European Respiratory Journal.
2006;28(6):1245–1257.
10. Global Initiative for Chronic Obstructive Lung Disease. Pneumologie. 2015;71(01):1–117.
11. Statistics Canada. Mortality, Summary List of Causes. Industry MO, ed. OECD Review of Fisheries 2011. July 2012:1–125.
13. Calverley P, Anderson JA, Celli B. Salmeterol and fluticasone
propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007;356(8):775–789.
14. Rennard SI, Daughton DM. Smoking cessation. Chest. 2000;117(5 Suppl 2):360S–4S.
15. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2013: Enforcing Bans on Tobacco Advertising, Promotion and Sponsorship. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013:376–399.
16. Vold ML, Aasebo U, Melbye H. Low FEV1, smoking history, and obesity are factors associated with oxygen saturation decrease in an adult population cohort. Int J Chron Obstruct Pulmon Dis.
2014;9:1225–1233.
17. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. In: Vol 163. 2001:1256–1276.
18. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Mölken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med.
2001;164(4):590–596.
19. C Fletcher RP. The natural history of chronic airflow obstruction. British Medical Journal. 1977;1(6077):1645–1648.
20. World Health Organization. Chronic obstructive pulmonary disease (COPD). Fact sheet No. 315. COPD. 2015;12(sup1):1–1.
21. Government of Canada HC. Canadian Tobacco Use Monitoring Survey (CTUMS) 2012. Journal of Aging Research. 2013;2012(4):1– 9.
22. Laurell C-B, Eriksson S. The Electrophoretic α 1-Globulin Pattern of Serum in α 1-Antitrypsin Deficiency. COPD. 2013;10(S1):3–8. 23. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin
deficiency. N Engl J Med. 2009;360(26):2749–2757.
1167.
25. MacNee W. Pathogenesis of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2005;2(4):258–266.
26. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. European Respiratory Journal. 2005;26(2):319–338. 27. Wanger J. Standardisation of the measurement of lung volumes.
European Respiratory Journal. 2005;26(3):511–522. 28. Nakano Y, Muro S, Sakai H, et al. Computed tomographic
measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1102–1108.
29. Kirby M, Pike D, Sin DD, Coxson HO, McCormack DG, Parraga G. COPD: Do Imaging Measurements of Emphysema and Airway Disease Explain Symptoms and Exercise Capacity? Radiology. 2015;277(3):150037–880.
30. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. European Respiratory Journal. 2000;16(2):269– 275.
31. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):770–777.
32. Laveneziana P, Webb KA, Ora J, Wadell K, O’Donnell DE. Evolution of Dyspnea during Exercise in Chronic Obstructive Pulmonary
Disease. Am J Respir Crit Care Med. 2011;184(12):1367–1373. 33. O’Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise
Hypercapnia in Advanced Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2002;166(5):663–668.
34. Neder JA, Arbex FF, Alencar MCN, et al. Exercise ventilatory
inefficiency in mild to end-stage COPD. Eur Respir J. 2015;45(2):377– 387.
35. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4(3):225–236.
37. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation:
pathophysiologic mechanisms. Am J Respir Crit Care Med. 1997;155(1):109–115.
38. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of Physical Activities in Daily Life in Chronic
Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2005;171(9):972–977.
39. Casaburi R, Petty TL. Principles and Practice of Pulmonary Rehabilitation. Vol 48. W.B. Saunders Company; 1993:508–862. 40. Maltais F, Decramer M, Casaburi R, et al. An Official American
Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2014;189(9):e15–e62.
41. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153(3):976–980.
42. MOSTERT R, GORIS A, WELING-SCHEEPERS C, Wouters EF, Schols AM. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 2000;94(9):859–867.
43. Vestbo J, Prescott E, Almdal T, et al. Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample. Am J Respir Crit Care Med. 2006;173(1):79–83.
44. Schols AMWJ, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–59.
45. Gea JG, Pasto M, Carmona MA, Orozco-Levi M, Palomeque J,
Broquetas J. Metabolic characteristics of the deltoid muscle in patients with chronic obstructive pulmonary disease. European Respiratory Journal. 2001;17(5):939–945.
46. Gosker HR, Zeegers MP, Wouters EFM, Schols AMWJ. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007;62(11):944–949.
Obstruct Pulmon Dis. 2008;3(4):637–658.
48. Korhonen MT, Cristea A, Alén M, et al. Aging, muscle fiber type, and contractile function in sprint-trained athletes. Journal of Applied Physiology. 2006;101(3):906–917.
49. Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis. 1991;143(1):9–18.
50. Maltais F, Jobin J, Sullivan MJ, et al. Metabolic and hemodynamic responses of lower limb during exercise in patients with COPD. Journal of Applied Physiology. 1998;84(5):1573–1580.
51. Gagnon P, Bussières JS, Ribeiro F, et al. Influences of Spinal Anesthesia on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2012;186(7):606–615.
52. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
53. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based
pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. An Intern Med. 2008;149(12):869–878. 54. Black-Shinn JL, Kinney GL, Wise AL, et al. Cardiovascular disease is
associated with COPD severity and reduced functional status and quality of life. COPD. 2014;11(5):546–551.
55. Cote CG, Casanova C, Marin JM, et al. Validation and comparison of reference equations for the 6-min walk distance test. European Respiratory Journal. 2008;31(3):571–578.
56. Polkey MI, Spruit MA, Edwards LD, et al. Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013;187(4):382–386.
57. Spruit MA, Watkins ML, Edwards LD, et al. Determinants of poor 6- min walking distance in patients with COPD: The ECLIPSE cohort. Respiratory Medicine. 2010;104(6):849–857.
58. Wouters EFM. COPD: from an organ- to a disease-oriented approach. COPD. 2008;5(2):73–74.
weight-bearing versus weight-supported exercise testing in patients with COPD. Respirology. 2015;21(3):483–488.
60. World Health Organization. Obesity and overweight. Fact Sheet No. 311. WHO. 2015.
61. World Health Organization. Global Status Report on
Noncommunicable Diseases. Vol 46. Geneva: WHO; 2014:e121– e122.
62. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972;25(6):329–343.
63. Shields M, Carroll MD, Ogden CL. Adult obesity prevalence in Canada and the United States. NCHS Data Brief. 2011;2(56):1–8.
64. C K Choi B, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada;Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Government of Canada, Ottawa, Ontario, Canada. Obesity in Canada. Vol 2. Public Health Agency of Canada; 2011:54–43.
65. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA.
2013;309(1):71–82.
66. Katzmarzyk PT, Ardern CI. Overweight and obesity mortality trends in Canada, 1985-2000. Can J Public Health. 2004;95(1):16–20.
67. Lau DCW, Douketis JD, Morrison KM, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ. 2007;176(8):S1–13.
68. Panel MDJMC-CE, Panel DHRMC-CE, Member CMAMFEP, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. JAC. 2014;63(Part B):2985– 3023.
69. Kaila B, Raman M. Obesity: a review of pathogenesis and
management strategies. Can J Gastroenterol. 2008;22(1):61–68. 70. Robert H Eckel MF, John M Jakicic P, Jamy D Ard MD, et al. 2013
71. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83(2):461S– 465S.
72. Cypess AM, Lehman S, Williams G, et al. Identification and
Importance of Brown Adipose Tissue in Adult Humans. N Engl J Med. 2009;360(15):1509–1517.
73. Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–887.
74. Heymsfield SB, Cefalu WT. Does body mass index adequately convey a patient's mortality risk? JAMA. 2013;309(1):87–88. 75. Dagenais GR, Yi Q, Mann JFE, Bosch J, Pogue J, Yusuf S.
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. American Heart Journal. 2005;149(1):54–60.
76. VAGUE J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4(1):20–34.
77. HEADY JA, MORRIS JN, RAFFLE PA. Physique of London busmen; epidemiology of uniforms. The Lancet. 1956;271(6942):569–570. 78. Cornier MA, Despres JP, Davis N, et al. Assessing Adiposity: A
Scientific Statement From the American Heart Association. Circulation. 2011;124(18):1996–2019.
79. Moon JR. Body composition in athletes and sports nutrition: an examination of the bioimpedance analysis technique. Eur J Clin Nutr. 2013;67(S1):S54–S59.
80. Chumlea WC, Guo SS. Bioelectrical impedance and body composition: present status and future directions. Nutr Rev. 1994;52(4):123–131.
81. Elia M. Body composition by whole-body bioelectrical impedance and prediction of clinically relevant outcomes: overvalued or underused? Eur J Clin Nutr. 2013;67 Suppl 1:S60–70.
82. MacDonald AJ, Greig CA, Baracos V. The advantages and limitations of cross-sectional body composition analysis. Current Opinion in Supportive and Palliative Care. 2011;5(4):342–349.
2014;34(10):2217–2223.
84. Fosbøl MØ, Zerahn B. Contemporary methods of body composition measurement. Clin Physiol Funct Imaging. 2014;35(2):81–97.
85. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. Journal of Applied Physiology. 1998;85(1):115–122.
86. Chowdhury B, Sjöström L, Alpsten M, Kostanty J, Kvist H, Löfgren R. A multicompartment body composition technique based on
computerized tomography. Int J Obes Relat Metab Disord. 1994;18(4):219–234.
87. Collins LC, Hoberty PD, Walker JF, Fletcher EC, Peiris AN. The effect of body fat distribution on pulmonary function tests. Chest.
1995;107(5):1298–1302.
88. Naimark A, Cherniack RM. Compliance of the respiratory system and its components in health and obesity. Journal of Applied Physiology. 1960;15(2):377–382.
89. Sharp jt, henry jp, sweany sk, meadows wr, pietras rj. the total work of breathing in normal and obese men. J Clin Invest. 1964;43(4):728– 739.
90. Li J, Li S, Feuers RJ, Buffington CK, Cowan GS. Influence of body fat distribution on oxygen uptake and pulmonary performance in morbidly obese females during exercise. Respirology. 2001;6(1):9–13.
91. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose Tissue: The New Endocrine Organ? A Review Article. Dig Dis Sci.
2008;54(9):1847–1856.
92. Friedman N, Fanning EL. Overweight and obesity: an overview of prevalence, clinical impact, and economic impact. Dis Manag. 2004;7 Suppl 1(supplement 1):S1–6.
93. Greenberg JA. Obesity and early mortality in the United States. Obesity. 2013;21(2):405–412.
94. Taylor VH, Forhan M, Vigod SN, McIntyre RS, Morrison KM. The impact of obesity on quality of life. Best Pract Res Clin Endocrinol Metab. 2013;27(2):139–146.
96. Lavie CJ. Obesity and heart failure prognosis: paradox or reverse epidemiology? European Heart Journal. 2004;26(1):5–7.
97. Mohebi R, Simforoosh A, Tohidi M, Azizi F, Hadaegh F. Obesity Paradox and Risk of Mortality Events in Chronic Kidney Disease Patients: A Decade of Follow-up in Tehran Lipid and Glucose Study. J Ren Nutr. 2015;25(4):345–350.
98. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):1856–1861.
99. Sava F, Laviolette L, Bernard S, Breton M-J, Bourbeau J, Maltais F. The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulm Med. 2010;10(1):55.
100. Liu Y, Pleasants RA, Croft JB, et al. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respiratory Medicine. 2015;109(7):851–859.
101. Calverley P, Anderson JA, Celli B. Salmeterol and fluticasone
propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007;356(8):775–789.
102. Furutate R, Ishii T, Wakabayashi R, et al. Excessive visceral fat accumulation in advanced chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:423–430.